EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therap

“This investment underscores our continued strong partnership with Ocumension for YUTIQ and DEXYCU in Asia,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “We are excited about the significant potential of these products in both the U.S. and in Asia and for our R&D pipeline, including the Phase 1 trial of EYP-1901 in wet age-related macular degeneration that is expected to commence in the coming months.”

010321 - EyePoint Pharmaceuticals Announ

.

Download • 81KB